CARY, N.C.--(BUSINESS WIRE)--April 27, 2006--A veteran team of five former Glaxo executives has joined Trana Discovery, Inc. (formerly known as Neos Discovery) to commercialize technology that identifies drug compounds that interrupt the lifecycle of pathogens through a novel mechanism of action - the inhibition of transfer ribonucleic acid (tRNA). The use of this technology can unlock the value - human and financial - hidden in drug compound libraries that can lead to new classes of drugs used to treat serious bacterial and viral infectious diseases.
